Stanley J. Goldsmith, M.D.

Nuclear Medicine

Publications

RECENT PUBLICATIONS:

ORIGINAL ARTICLES:

1.   Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Research. 2000; 60: 5237 - 5243.

2.   Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

   Eur J Nucl Med 2000; 27:1564-1578.

3.   Kostakoglu L, Goldsmith SJ: Positron Emission Tomography in Lymphoma: Comparison with computed tomography and Gallium-67 Single Photon Emission Computed Tomography Clinical Lymphoma 2000; 1: 67-74

4.   Kostakoglu L, Goldsmith SJ: Imaging multidrug resistance in hematological malignancies

Hematology 2001; 6: 111-124

5.   Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-888.

6.   Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ: Positron emission tomography [PET] predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43: 1018-1027

7.   Kostakoglu L, Goldsmith SJ: 18F-FDG-PET Evaluation of response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 2003; 44: 224-239

8.   Kostakoglu L, Agress H, Goldsmith SJ: Clinical Role of FDG-PET in the evaluation of cancer patients. Radiographics 2003; 22: 315-340

9.   Leonard JP, Siegel JA, Goldsmith SJ: Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with nonHodgkin’s Lymphoma. Cancer Investigation 2003; 21: 241-252

10.   Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S,

Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy:

targeting prostate specific membrane antigen. J Urology 2003; S88-98

11.   Bander NH. Nanus DM. Milowsky MI. Kostakoglu L. Vallabahajosula S. Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Sem Oncol 2003; 30:667-76

12.   Bander NH, Trabuli EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P,

Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urology 2003; 170:1717-21

13.   Smith-Jones PM. Vallabhajosula S. Navarro V. Bastidas D. Goldsmith SJ. Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44:610-617

14.   Vallabhajosula S. Smith-Jones PM. Navarro V. Goldsmith SJ. Bander NH.

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal

antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004; 58:145-55

15.   Kostakoglu L. Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med: 2004; 45: 56-68

16.   Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ: The role of FDG-PET Imaging in the management of lymphoma. Clin Advances in Hem & Onc 2004; 2:115-121

17.   Vallabajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J Nucl Med. 2005; 46: 634-41

INVITED ARTICLES:

1.   Goldsmith SJ, Kostakoglu L: Role of Nuclear Medicine in the Evaluation of the Solitary Pulmonary Nodule Seminars in Ultrasound, CT and MRI 2000; 21: 129-138

2.   Goldsmith SJ, Kostakoglu L: Nuclear Medicine Imaging of Lung Cancer

Radiologic Clinics of North America 2000; 38: 511-524

3.   Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ. Procedure Guideline for Somatostatin receptor scintigraphy with 111In-pentetreotide J Nucl Med 2001; 42: 1134-1138

4.   Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Sem Nucl Med 2001; 31:177-190.

5.   Goldsmith SJ: Status of Radiolabeled Peptides in Diagnosis and Therapy Sem Nucl Med 2002; 32: 78 [Guest Editorial]

6.   Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ: The utility of monoclonal antibodies in the imaging of prostate cancer. Sem Urol Onc 2002; 20:211-218

7.   Goldsmith SJ, Kostakoglu L, Somrov S, Palestro C: Radionuclide Imaging of Thoracic Malignancies. Chest Surgery Clinics of North America 2004; 14: 95-

8.   Goldsmith SJ. Improving Insight into Radiobiology and Radionuclide Therapy. J Nucl Med 2004; 45: 1104-1105

9.   Goldsmith SJ, Kostakoglu L, Somrov S, Palestro C: Radionuclide Imaging of Thoracic Malignancies. Radiologic Clinics of North America 2005; 43: 571-588

BOOK CHAPTERS:

1.   Goldsmith SJ. Thyroid Carcinoma: Diagnosis, Management and Therapy, pgs 197 - 220 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000

2.   Goldsmith SJ, Bander N: Prostate Carcinoma: Therapy with Radiolabelled Monoclonal Antibodies, pgs 433 - 440 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000

3.   Goldsmith SJ. Nuclear Oncology: An Overview, pgs 1 - 12 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000

4.   Goldsmith SJ, Kostakoglu L. Nuclear Medicine in the Diagnosis and Management of Colorectal Cancer, pgs 157-177 in Saltz L [Ed]: Colorectal Cancer: Multimodality Management, Humana Press (Totowa, NJ), 2002

5.   Goldsmith SJ, Bar-Shalom R, Kostakoglu L, Weiner R, Neumann R: Gallium-67 Scintigraphy in Tumor Detection, pgs 911-929 in Sandler M, Coleman R e al [eds] Diagnostic Nuclear Medicine, Lippincott Williams and Wilkins (Philadelphia) 2003

6.   Kostakoglu L, Goldsmith SJ: Staging and Followup of Lymphoma with [F-18]Fluorodeoxyglucose PET and Gallium-67 Imaging, pgs 29-74, in Freeman, L [ed] Nuclear Medicine Annual 2003, Lippincott Williams & Wilkins (Philadelphia) 2003

7.   Goldsmith SJ. The Endocrine System, pgs 350-385 in Bernier DR, Christian PE, Langan JK: Nuclear Medicine and PET: Technology and Techniques, 5th edition, Mosby (St. Louis), 2003

Back to topBack To Top